Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CD5-targeted Kv1.3 mRNA lipid nanoparticles
- Development stage
- Preclinical
- Lead developer
- University of Cincinnati
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intratumoral
01
Overview
CD5-targeted Kv1.3 mRNA lipid nanoparticles (CD5-NPs) is an investigational targeted mRNA nanotherapy developed by researchers at the University of Cincinnati for the treatment of head and neck squamous cell carcinoma (HNSCC). In HNSCC, tumor-infiltrating T cells are functionally impaired, in part due to the downregulation of Kv1.3 potassium channels, which are essential for calcium-dependent effector functions. This therapy consists of lipid nanoparticles functionalized with anti-CD5 antibodies to selectively target T cells, encapsulating in vitro-transcribed mRNA encoding the Kv1.3 potassium channel. Upon internalization by T cells, the nanoparticles deliver the mRNA into the cytosol, restoring Kv1.3 expression and activity. This restoration enhances calcium influx, leading to increased secretion of effector cytokines and cytotoxic molecules, thereby overcoming immune dysfunction and promoting anti-tumor activity.
- Other names
- CD5-NPsCD-5-NPsCD 5-NPsCD5-targeted Kv1.3 mRNA LNPsCD-5-targeted Kv1.3 mRNA LNPsCD 5-targeted Kv1.3 mRNA LNPsCD5-targeted Kv1.3 mRNA lipid nanoparticlesCD-5-targeted Kv1.3 mRNA lipid nanoparticlesCD 5-targeted Kv1.3 mRNA lipid nanoparticlesKv1.3 mRNA-loaded CD5-NPsKv-1.3 mRNA-loaded CD5-NPsKv 1.3 mRNA-loaded CD5-NPs
02
Targets
CD5 (T-cell surface glycoprotein CD5)GZMB (Granzyme B)KCNA3 (Potassium voltage-gated channel subfamily A member 3)NFAT (NFAT family)
Beyond the preview
Go deeper on CD5-targeted Kv1.3 mRNA lipid nanoparticles.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CD5-targeted Kv1.3 mRNA lipid nanoparticles.